Original Articles
29 March 2011
Vol. 1 No. 1 (2011)
https://doi.org/10.4081/dts.2011.e3

Effect of the neridronate on RANKL release in differentiated primary human osteoblasts

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
2234
Views
511
Downloads
1311
HTML

Authors

Vanessa Nicolin
nicolin@units.it
Department of Biomedicine, .
Roberto Valentini
University of Trieste, Clinical Department of Specialized Surgical Sciences, Biomaterials and Bioimplants, Trieste, Italy.
Roberta Bortul
Clinical Department of Biomedicine, section of Molecular Biology, Trieste, Italy.
Giovanni Fancellu
University of Trieste, Clinical Department of Specialized Surgical Sciences, Trieste, Italy.
Bisphosphonates are important inhibitors of bone resorp- tion and widely used clinically to treat osteoporosis, metabolic bone diseases and other orthopaedic disorders . Inhibiting osteoclasts via the mevalonate pathway is recognized as the primary mechanism of its inhibitory action. Recent evidence suggests that bisphosphonates may regulate essential signaling molecules involved in osteoclastogenesis such as RANKL (receptor activator of NF-kB ligand) which are synthesized by osteoblasts. In this report we have investigated into the neridronate-osteoblast interactions in modulating essential signaling molecule such as RANKL.

Altmetrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



Effect of the neridronate on RANKL release in differentiated primary human osteoblasts. (2011). Drugs and Therapy Studies, 1(1), e3. https://doi.org/10.4081/dts.2011.e3